Ronald C. Renaud, Jr., M.B.A. is Chair of our board of directors and has served on our board of directors since November 2021. Since October 2024, Mr. Renaud has served as President and Chief Executive Officer and a member of the board of directors at Kailera Therapeutics, Inc., a biotechnology company. Prior to this, Mr. Renaud served as President and Chief Executive Officer and a member of the board of directors of Cerevel Therapeutics Holdings, Inc. (acquired by AbbVie Inc.), a biopharmaceutical company, from June 2023 until August 2024. Prior to this, Mr. Renaud was a partner at Bain Capital Life Sciences, a healthcare and life sciences investment firm, from September 2022 through June 2023. Prior to this, he served as Chair and Chief Executive Officer of Translate Bio from 2014 until its acquisition by Sanofi in September 2021. Prior to this, Mr. Renaud was at Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from 2007 through 2014, where he served as Chief Financial Officer, Chief Business Officer and, finally, President and Chief Executive Officer at the time of its acquisition by Merck & Company, Inc., a global healthcare company (Merck). Prior to this, Mr. Renaud was a biotechnology equity research analyst at investment banking firms J.P. Morgan, Schwab Soundview and Bear Stearns from January 2000 until February 2006. Mr. Renaud also served in various positions at Amgen Inc., a biotechnology company, from April 1994 until December 1999. Mr. Renaud previously served on the boards of biopharmaceutical companies Atara Biotherapeutics, Inc. from April 2020 until December 2022 and Ikena Oncology, Inc. from March 2018 until December 2022. Mr. Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California. We believe Mr. Renaud is qualified to serve on our board of directors because of his leadership and management experience and his extensive knowledge of the biopharmaceutical industry.